Table 2 Baseline characteristics of patients with chondroblastic Osteosarcoma after propensity score matching (195 patients).
Variable | Those who received adjuvant Chemotherapy therapy (144 patients) | No/unknown Chemotherapy therapy (51 patients) | Overall (195 patients) | P-value |
|---|---|---|---|---|
Age, years (mean ± SD) | 32.16 ± 17.84 | 41.90 ± 22.89 | 34.71 ± 19.70 | 0.057 |
Sex | 0.436 | |||
Male | 76 (52.8%) | 23 (45.1%) | 99 (50.8%) | |
Female | 68 (47.2%) | 28 (54.9%) | 96 (49.2%) | |
Race | 0.996 | |||
White | 111 (77.1%) | 39 (76.5%) | 150 (76.9%) | |
Black | 22 (15.3%) | 8 (15.7%) | 30 (15.4%) | |
Others | 11 (7.6%) | 4 (7.8%) | 15 (7.7%) | |
Marital status | 0.573 | |||
DSW | 10 (6.9%) | 5 (9.8%) | 15 (7.7%) | |
Married | 54 (37.5%) | 22 (43.1%) | 76 (39.0%) | |
Single | 77 (53.5%) | 22 (43.1%) | 99 (50.8%) | |
Unknown | 3 (2.1%) | 2 (3.9%) | 5 (2.6%) | |
Radiotherapy | 0.885 | |||
Yes | 14 (9.7%) | 6 (11.8%) | 20 (10.3%) | |
No/Unknown | 130 (90.3%) | 45 (88.2%) | 175 (89.7%) | |
Stage | 0.928 | |||
I–II | 26 (18.1%) | 10 (19.6%) | 36 (18.5%) | |
III–IV | 4 (2.8%) | 1 (2.0%) | 5 (2.6%) | |
Unknown | 114 (79.2%) | 40 (78.4%) | 154 (79.0%) | |
Grade | 0.520 | |||
I–II | 10 (6.9%) | 6 (11.8%) | 16 (8.2%) | |
III–IV | 73 (50.7%) | 26 (51.0%) | 99 (50.8%) | |
Unknown | 61 (42.4%) | 19 (37.3%) | 80 (41.0%) | |
Income | 0.886 | |||
< $75,000 | 38 (26.4%) | 11 (21.6%) | 49 (25.1%) | |
$75,000–90,000 | 41 (28.5%) | 15 (29.4%) | 56 (28.7%) | |
≥ $90,000 | 36 (25.0%) | 15 (29.4%) | 51 (26.2%) | |
Unknown | 29 (20.1%) | 10 (19.6%) | 39 (20.0%) | |
Rural–urban continuum | 0.981 | |||
Metropolitan areas | 94 (65.3%) | 33 (64.7%) | 127 (65.1%) | |
Nonmetropolitan counties | 21 (14.6%) | 8 (15.7%) | 29 (14.9%) | |
Unknown | 29 (20.1%) | 10 (19.6%) | 39 (20.0%) |
